.png&w=384&q=75)
Recommended for treating venous circulation disorders (swollen legs, pain, nocturnal cramps) and for treating symptoms due to acute hemorrhoidal attack.
Oral route. The tablets should be taken at meal times.
Venous insufficiency: 2 tablets daily, one at mid-day and one in the evening.
Acute hemorrhoidal attack: A 4-day course of 6 tablets daily, followed by 4 tablets daily over the next 3 days.
In all cases, strictly comply with the doctor's prescription.
The patient must always tell the doctor or pharmacist about any other treatment the patient is receiving.
No interaction studies have been performed. No clinically relevant drug interaction has been reported to date from post marketing experience on the product.
Hypersensitivity to the active substance or to any of the excipients.
Possible side effects: Like all medicines, Diosmin + Hesperidin (Daflon 500 mg) can cause side effects, although not everybody gets them. If any of the side effects gets serious, or if the patient notices any side effects not listed in this leaflet, please tell the doctor or pharmacist.
Diosmin + Hesperidin (Daflon 500 mg) is usually well tolerated.
The following side effects can appear: Common (less than one out of 10, but more than one out of 100 users): diarrhea, dyspepsia, nausea, vomiting.
Uncommon (less than one out of 100, but more than one out of 1,000 users): colitis (inflammation of colon).
Rare (less than one out of 1,000, but more than one out of 10,000 users): dizziness, headache, malaise, rash, pruritus, urticaria.
Frequency not known: abdominal pain, isolated face, lip, eyelid edema (swelling). Exceptionally, Quincke's edema (rapid swelling of tissues such as the face, lips, mouth, tongue or throat that may result in breathing difficulty).
Pregnancy: There are no limited amounts of data from the use of Micronised Purified Flavonoid Fraction in pregnant women.
Animal studies do not indicate reproductive toxicity.
As a precautionary measure, it is preferable to avoid the use of Daflon during pregnancy.
Breast-feeding: It is unknown whether the active substance/metabolites are excreted in human milk.
A risk to the newborns/infants cannot be excluded.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Daflon therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.